Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Yu Y, Song J, Guo X, Wang S, Yang X, Chen L et al
The cohort included two sub-groups ( n = 8 per sub-group) based on length of response to CAR T cells, with short-term responders (STR) having CD19+ leukemia relapse within 142 30 days following initial response and long-term responders (LTR) maintaining remission without subsequent therapy post-CAR T cell infusion
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
Retatrutide is generating enormous buzz because its early clinical trial data shows weight loss numbers that nobody in this space has seen before
How to cancel An easy cancellation process means theyre confident in results, not relying on your inertia to keep you paying
